Drug Trial Radar · NCT04612751
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
155
Actual
Start
Feb 2, 2021
Primary completion
May 4, 2026
Study completion May 4, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Nov 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy with or without carboplatin in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Conditions
- Advanced or Metastatic NSCLC
Interventions
Datopotamab deruxtecanDrug
Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
DurvalumabDrug
Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
CarboplatinDrug
Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle
AZD2936Drug
Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
MEDI5752Drug
Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
AZD7789Drug
Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with DLTs; TEAEs and other safety parameters during the study.Time frame: DLTs: within first cycle (21 days); TEAEs and other safety parameters: when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up (approximately 60 months)
Locations
42 sites in 8 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California
Research Site
Santa Ana, California
Research Site
St Louis, Missouri
Research Site
Hackensack, New Jersey
Research Site
Cleveland, Ohio
Research Site
Philadelphia, Pennsylvania
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
San Antonio, Texas
Research Site
Fairfax, Virginia
Research Site
Hasselt, Belgium
Research Site
Roeselare, Belgium
Research Site
Aviano, Italy
Research Site
Meldola, Italy
Research Site
Orbassano, Italy
Research Site
Roma, Italy
Research Site
Kōtoku, Japan
Research Site
Sunto-gun, Japan
Research Site
Yokohama, Japan
Research Site
Gdansk, Poland
Research Site
Lodz, Poland
Research Site
Lublin, Poland
Research Site
Warsaw, Poland
Research Site
A Coruña, Spain
Research Site
Badalona, Spain
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Seville, Spain
Research Site
Hsinchu, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan, Taiwan
Research Site
Adana, Turkey (Türkiye)
Research Site
Ankara, Turkey (Türkiye)
Research Site
Ankara, Turkey (Türkiye)
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.